<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recent trends in the diagnosis and management of gastrointestinal <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>Primary gastrointestinal <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accounts for 30-40% of <z:hpo ids='HP_0000001'>all</z:hpo> extranodal <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, while it comprises only 1-8% of <z:hpo ids='HP_0000001'>all</z:hpo> gastrointestinal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The most common histological type is mucosa-associated lymphoid tissue <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, followed by diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, the incidence of intestinal follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has been increasing </plain></SENT>
<SENT sid="4" pm="."><plain>Balloon-assisted endoscopy and capsule endoscopy are essential tools for the assessment of small bowel <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment modalities for gastrointestinal <z:hpo ids='HP_0002665'>lymphomas</z:hpo> include 'watch and wait' strategy, antibiotics (e.g. Helicobacter pylori eradication), radiotherapy, chemotherapy, surgical resection, immunotherapy (e.g. rituximab), and combinations of these </plain></SENT>
<SENT sid="6" pm="."><plain>Optimal therapeutic strategies should be determined based on the involved site, histological type, and clinical stage </plain></SENT>
<SENT sid="7" pm="."><plain>It should be noted that accurate pretreatment diagnosis of the disease is most important </plain></SENT>
</text></document>